PTPN6 and myeloid sarcoma: Furthermore, treatment of PBMCs from MS patients with IFNβ (a current treatment for MS) induces SHP-1 activity with corresponding reduced inflammatory gene expression, and the therapeutic effect of IFNβ is also dependent on SHP-1 (Christophi et al., 2009).